Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

On Monday, Exact Sciences (NASDAQ:EXAS) Corporation (NASDAQ:EXAS) shares received a reaffirmed Buy rating and a steady price target of $75 from Canaccord Genuity. The endorsement comes following ...

On Monday, BTIG updated its outlook on Exact Sciences Corp (NASDAQ:EXAS), increasing the price target to $82 from the previous $70 while reiterating a Buy rating on the stock. The adjustment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A 40-year-old widow and her young daughter were found dead in their home in Manipur's Imphal West district on Monday.

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

Bittersweet experiences aren’t uncommon. Do people ever truly feel both positive and negative at the same exact moment, or do ...